On 26 May, Alzheimer Europe held a session of its online workshop series the Alzheimer's Association Academy, entitled "Not all dementias are Alzheimer’s disease”.
Our Academies are a popular series of online capacity-building workshops bringing together representatives of national Alzheimer’s associations with members of the European Working Group of People with Dementia (EWGPWD) and European Dementia Carers Working Group (EDCWG), as well as representatives from pharmaceutical companies, to learn about dementia advocacy, care, policy, research and treatment.
Project Officer Cindy Birck chaired the session, welcoming close to 40 participants from 15 countries and two companies (Anavex and Bristol Myers Squibb), as well as several members of staff from Alzheimer Europe.
Speakers at the session included:
Phil Angrave, a member of the EWGPWD, who shared his lived experience following a diagnosis of Dementia with Lewy-bodies (DLB), and of some of the difficulties he has faced, having a ‘non-Alzheimer’s type’ of dementia
Evelien Lemstra, a neurologist at Amsterdam University Medical Center (Amsterdam UMC), who shared a clinician’s view on DLB as well as on Parkinson’s disease dementia
Harro Seelaar, a neurologist at Erasmus University Medical Center (Erasmus MC), who shared a clinician’s view on Frontotemporal dementia (FTD)
and Jill Carson, Consultant in Public Policy for Alzheimer Scotland, who discussed the recent policy report “Childhood dementia in Scotland 2025”.
Following each of these informative and insightful presentations, there was ample opportunity for questions to the speakers.
We hope everyone enjoyed the session and we would like to say a huge thank you to all speakers and to our Gold and Silver sponsors, Bristol Myers Squibb, Eisai, Johnson & Johnson, Eli Lilly and Company, and Roche as well as to the European Union’s Citizen’s, Equalities, Rights and Values (CERV) programme, without whom our Academy sessions would not be possible.
